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Abstract 
Introduction: Leptin regulates the organism’s immune response. Juvenile idiopathic arthritis (JIA) is a chronic joint disease in children, 
leading to chronic changes in motor organs. 
Material and methods: In children with JIA (n = 42) and healthy subjects (n = 28), leptin concentration (LEP), body mass index (BMI), 
haematocrit (HTC), haemoglobin (HB), morphotic elements (WBC,LYMPH), erythrocyte sedimentation rate (ESR), and ANA Hep-2 
antibodies were analysed. JIA group was divided into: children with a longer (51–148 months) (IA) n = 22 and a shorter disease period 
(2-18 months) (IB) n = 20. 
Results: Only 58.3% of the IA and 50% of the IB group had ANA Hep-2 confirmed. The ill children had higher and more diversified 
LYMPH and ESR levels compared to the healthy children. The highest LEP for the IA group was 37.5 ng/cm3, (Me 5.85), for IB — 40.10 
ng/cm3, (Me 2.46) as compared to the IC — 3.74 ng/cm3 (Me 2.85), respectively. The average BMI value for the IA group was 16.61 kg/m2, 
for IC it was 18.91 kg/m2, and the median for IB was 15.89 kg/m2. Children with BMI values < 23 kg/m2 from the IA and IB group had a 
reduction in LEP as compared to control group (p = 0.04). The relationship between the illness and LEP diversification per BMI unit was 
found in both groups. Children with a shorter illness period had higher LEP differentiation per BMI unit compared to the healthy children.
Conclusions: 
1. Children with juvenile idiopathic arthritis with BMI < 23 kg/m2 had lower leptin concentrations than healthy subjects. 
2. Ill children with a shorter-term disease had a higher diversification of leptin concentration per BMI unit as compared to healthy controls. 
(Endokrynol Pol 2015; 66 (5): 417–421)
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Streszczenie
Wstęp: Leptyna reguluje odpowiedź immunologiczną organizmów. Młodzieńcze idiopatyczne zapalenie stawów (MIZS) jest przewlekłą 
chorobą stawów u dzieci prowadzącą do przewlekłych zmian w narządach układu ruchu.
Materiał i metody: U dzieci z MIZS (n = 42) i zdrowych osobników (n = 28) analizowano następujące parametry: stężenie leptyny (LEP), 
wskaźnik masy ciała (BMI), hematokryt (HTC), zawartość hemoglobiny (HB), liczba elementów morfotycznych krwi (WBC, LYMPH), 
odczyn OB i obecność przeciwciał ANA Hep-2. Grupę MIZS podzielono na: dzieci dłużej chorujące (51–148 miesięcy) n = 22 (IA) i krócej 
chorujące (2–18 miesięcy) n = 20 (IB). 
Wyniki: Tylko u 58,3% dzieci grupy IA i 50% dzieci grupy IB potwierdzono obecność przeciwciał przeciwjądrowych ANA Hep-2. 
U chorych dzieci wykazano wyższe poziomy LYMPH i OB oraz większe zróżnicowanie wyników, w porównaniu do dzieci zdrowych. 
Najwyższe stężenie LEP dla grupy IA wynosiło 37,50 ng/cm3, (Me 5,85) dla IB 40,10 ng/cm3, (Me2,46), w porównaniu z IC, gdzie wyno-
siło odpowiednio 3,74 ng/cm3 (Me 2,85). Średnia wartość BMI dla grupy IA wynosiła 16,61 kg/m2, dla IC 18,91 kg/m2, a mediana dla IB 
15,89 kg/m2 . U dzieci z BMI < 23 kg/m2, grupy IA i IB, stwierdzono niższe stężenia leptyny w porównaniu z grupą kontrolną (p = 0,04). 
Stwierdzono wpływ schorzenia na zróżnicowanie stężenia leptyny w przeliczeniu na BMI w obu grupach dzieci chorych. U chorych dzieci, 
z krótszym czasem trwania choroby, wykazano większe zróżnicowanie wartości stężenia leptyny w przeliczeniu na BMI, niż u zdrowych.
Wnioski: 
1. Dzieci z młodzieńczym idiopatycznym zapaleniem stawów z BMI<23 kg/m2 mają niższe stężenie leptyny niż dzieci grupy kontrolnej. 
2. Dzieci z MIZS z krótszym czasem trwania choroby, charakteryzują się większym zróżnicowaniem stężenia leptyny w przeliczeniu na 
jednostkę BMI, w porównaniu ze zdrowymi dziećmi. (Endokrynol Pol 2015; 66 (5): 417–421)
Słowa kluczowe: młodzieńcze idiopatyczne zapalenie stawów; leptyna; BMI
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Material and methods
The tests in this study were performed on a group of 
42 children with JIA across different ages; 28 healthy 
children (IC) constituted the control group. The study 
was approved by the Local Committee of Bioethics. All 
ill children received a non-steroidal anti-inflammatory 
drug (methotrexate).
The children were divided into two subgroups: the 
IA group consisted of children with a longer disease 
period (51–148 months) and the IB group consisted of 
children with a shorter disease period (2–18 months). 
The children from the IA group were between 7 and 
18 years old (average: 13 years old), the children from 
the IB group were between 4 and 17 years old (aver-
age: 10 years old), and the children in the control group 
were between 8 and 15 years old (average: 11 years old). 
The nutritional condition of the examined groups was 
assessed by body mass index (BMI) calculation kg/m2. 
During the tests, venous blood was collected from the 
children, of which the following indicators were deter-
mined: haematocrit (HTC), haemoglobin (HGB), eryth-
rocyte sedimentation rate (ESR), and concentrations of 
leukocytes and lymphocytes (WBC and LYMPH). LEP 
was determined and tests for ANA Hep-2 antinuclear 
antibodies were also performed. For test purposes, 
elbow vein blood was taken and put through three 
kinds of Vacutainer test tubes; two of them contained 
anticoagulants (EDTA-K2 solution or 3.8% sodium cit-
rate solution) that prevent blood clotting.
In the EDTA-K2 solution-containing tests HTC, WBC 
was determined, whereas in sodium citrate solution-
containing tests, ESR was determined. WBC quantity 
and HB content in the analysed samples was assessed 
with the use of a haematology analyser, BC 2300. ESR 
was assessed from erythrocyte sedimentation time in 
Westergen tubes from blood collected and mixed with 
3.8% sodium citrate solution (4:1). This assessment was 
made one hour after putting a given sample on a rack 
and was calculated in mm/h.
In order to obtain serum, blood was kept from clot-
ting in room temperature for 30 min. and centrifuged in 
3000 rpm for 15 min. at 4 ± 2ºC, after which the serum 
was separated and put into clean test tubes. Then, it 
was examined for LEP and the presence of ANA-Hep2 
antinuclear antibodies. LEP was measured using an 
ELISA test designed by LINCO Research Inc. LEP in the 
tested samples was determined on the basis of a refer-
ence curve interpolation created by the same analysis 
with the use of a standard solution of human leptin in 
at concentrations of 1–100 ng/cm3. The presented results 
are average values from three analyses.
For the tests on ANA-Hep2 antinuclear antibodies 
in serum, the Colorzyme HEp-2 ANA test of Immuno 
Introduction
The obesity gene (ob) is responsible for proleptin bio-
synthesis, the leptin precursor. Leptin generation mainly 
occurs in subcutaneous adipose tissue adipocytes and in 
the placenta trophoblast; it may be also synthesised in 
gastric epithelial cells and in the female mammary glands. 
Its small distribution has been confirmed in areas of the 
hypothalamus, pituitary gland, liver, and striated tissue 
[1–4]. One of its lesser-known functions is its immune 
system regulatory function. Leptin reduction due to adi-
pose tissue decrease or nutritional restrictions may cause 
immune disorders and may increase the risk of contagious 
diseases by affecting acquired and inborn immunity or by 
stimulating both pro- and anti-inflammatory effects [5, 6]. 
Leptin intensifies the inflammatory response by monocyte 
and macrophage activation, which, under its influence, 
increases production of pro-inflammatory cytokines, 
such as TNF-α, IL-1, and IL-6 [7–9]; it also regulates 
growth, proliferation, and activation of T lymphocytes. 
Leptin also affects direct T cell differentiation to the Th1 
phenotype, which intensifies inflammation by releasing 
IL-2 and interferon G, as well as prevents steroid-induced 
lymphocytes apoptosis [6, 10, 11]; however, it also has 
certain anti-inflammatory properties, which are related 
to IL-1 receptor antagonist release [6].
Due to the double role of leptin in the inflamma-
tory process, it is difficult to assess its total impact on 
immune response. Leptin performs different functions 
on acute and chronic inflammations, as it has been 
observed at increased concentrations during acute inflam-
mation, such as in sepsis or in septic shock. The released 
cytokines stimulate leptin production in the adipocytes, 
where leptin causes cytokine post-inflammatory effects 
by its intensified production in macrophages, thus giv-
ing patients a greater chance to survive acute inflamma-
tion [3, 6, 12]. There are, however, data indicating that 
chronic inflammatory diseases may cause a reduction in 
leptin concentration, perhaps due to the fact that long-
term adipose tissue stimulation with pro-inflammatory 
cytokines limits leptin production [13–15]. 
Juvenile idiopathic arthritis (JIA) is a chronic joint 
disease starting before the age of 16 and lasting for at 
least 6 weeks or 3 months and causing chronic changes 
to motor organs [16–18]. Due to improper anti-inflam-
matory functioning in rheumatic disease, macrophage 
and T lymphocyte activation occurs which causes pro- 
and anti-inflammatory factor balance disruption, the 
consequence of which is activation of other immune 
system cells and inflammatory processes [19, 20].
The aim of the study was to assess leptin concen-
tration, body mass index, haemoglobin, morphotic 
elements, and ANA Hep-2 antibodies in children with 
juvenile idiopathic arthritis (JIA). 
419
Endokrynologia Polska 2015; 66 (5)
PR
A
C
E 
O
RY
G
IN
A
LN
E
Concepts N.A. Ltd. was used, which consisted of anti-
nuclear antibodies identification by indirect immuno-
fluorescence and observing characteristic luminosity 
in fluorescent microscope, confirming the presence of 
autoantibodies. 
In order to determine the relationships between 
random variables, LEP, illness duration, sex, age, and 
BMI, as well as WBC, LYMPH, HBG, HCT, and ESR, 
were assessed and parametric methods were used 
(single direction ANOVA, t test for independent groups, 
and Pearson’s linear correlation coefficient,) as well as 
non-parametric methods (Kruskal-Wallis ANOVA test 
and median test, Mann-Whitney U test, Kolmogorov-
Smirnov test, Waldo-Wolfowitz test, ranks correlations, 
ranks correlation Spearman coefficient,  τ Kendall test, 
and Fisher ’s exact test). The following correlations 
were also tested: LEP, LEP/BMI, LEP/age, and LEP/ 
/time, as well as WBC, LYMPH, HBG, HCT, and ESR in 
the healthy and ill children (longer illness period: IA; 
shorter illness period: IB). The relationship between 
health conditions (healthy, ill IA, and IB) was assessed 
using the following measurements: WBC, LYMPH, 
HBG, HCT, and ESR. The differences between LEP 
values within general populations of ill (IA+IB) and 
healthy children (IC) as well as between IA and IC and 
IB and IC were also examined. For all statistical analyses 
the α = 0.05 significance level was determined.
Tests were also carried out to assess the effect of 
BMI on LEP values. The difference in LEP value per 
BMI unit LEP/BMI was evaluated for the healthy and 
ill children. The correlation between LEP, LEP/BMI, and 
age, as well as LEP, LEP/BMI, and disease period, was 
assessed either in healthy or ill children (IA, IB). The in-
fluence of health condition on LEP/age was assessed in 
the healthy (IC) and ill children (IA, IB), as well as in the 
healthy (IC) and ill children (IA + IB). The relationship 
between LEP and BMI was estimated (IA + IB + IC). 
On the basis of scientific writing, the LEP standard 
value for the following group of children was deter-
mined: BMI < 23 kg/m2 — below 5 ng/cm3. Based on this 
value, LEP normal values were assessed (exclusively 
BMI < 23 kg/m2), as well as those that exceeded this 
standard. The relationship between health condition 
(healthy, ill) and LEP (standard, increased) was deter-
mined [23–25]. 
Results
Antinuclear antibodies (ANA) were determined for 
58.3% of the IA group children and for 50% of the IB 
group children, but antibodies were not detected in 
the control group. 
The effect of health condition on the random vari-
able LYMPH was established, with assumed validity 
level α: Kruskal-Wallis test H = 17.3, p = 0.0002; me-
dian test, χ2 = 11.4, p = 0.003. On the basis of p value 
estimation for multiple (collateral) comparisons, we 
found that there is a statistical validity of difference 
between tested healthy (IC) and ill child populations 
(IA) (p < 0.0003) as well as between tested healthy (IC) 
and ill child populations (IB) (p < 0.003), considering 
the LYMPH random variable for assumed α validity. 
The effect of a health condition on the ESR random 
variable was proven, with assumed α validity: Kruskal-
Wallis test H = 14.9, p = 0.0006; median test, χ2 = 8.96, 
p = 0.011. On the basis of p value assessment for mul-
tiple (collateral) comparisons, it was proven that there 
is statistical validity between tested healthy (IC) and ill 
children (IA) (p < 0.0008), as well as between healthy 
(IC) and (IB) ill children (p < 0.006), considering the ESR 
random variable, with assumed α validity. 
The results and relationships obtained are shown in 
Table I. The highest LEP value in the IA group was 37.50 
ng/cm3 and the lowest was 1.24 ng/cm3. In the serum of 
children from the IB group these concentrations came to 
40.1 ng/cm3 and 0.93 ng/cm3, respectively. In the control 
group the highest LEP value was 3.74 ng/cm3 and the 
lowest was 2.4 ng/cm3. 
Using a t test for independent samples, for non-
homogeneous variances, a statistical validity of LEP 
random variables was determined in ill children (IA 
and IB) with a BMI < 23 kg/m2, as well as the popula-
tion of healthy children, for assumed validity level α 
(p = 0.04). The statistical feature of LEP difference val-
ues for samples taken from the tested populations was 
–0.91. The difference of expected LEP random variables 
in the tested population of ill children (B) with a BMI 
< 23 kg/m2 and healthy children with a BMI < 23 kg/m2 
was assessed by estimation of confidence interval (CI), 
which was 0.95 (–1.73–0.08).
 In our own research, using the Waldo-Wolfowitz 
test we established the statistical validity of differences 
between ill children (IA + IB) and healthy children, 
considering the LEP random variable per BMI unit, 
with the assumed validity level of α, p = 0.01. The as-
sessed groups differed from each other in LEP random 
variable per BMI unit, not only on expected medians, 
but also on probability distribution form, e.g. random 
variable value diversification.
Discussion
There is very little information available in the lit-
erature about leptin concentrations in the serum of 
children with JIA. The reported data mainly focus 
on adults suffering from rheumatoid arthritis [16,21]. 
There is some data suggesting that LEP levels are low-
er in patients suffering from RA or JIA, as confirmed 
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by the Perfetto et al. research team which assessed LEP 
levels in children suffering from JIA [17], whereas Ni-
shiya et al. and Anders et al. did not find any significant 
differences between LEP levels of healthy patients and 
patients suffering from RA [18, 22]. Our research has 
indicated the presence of ANA antinuclear antibod-
ies in 58.3% of children with long-term JIA, as well 
for 50% of children with short-term disease, whereas 
there was no presence detected in the control group. 
The relation between the tested disease and level of 
LYMPH and ESR level has been determined. The ill 
children proved to have higher LYMPH and ESR with 
much higher diversification of both, in comparison 
with healthy children. 
Table I. Statistical results for the assessed populations of children with juvenile idiopathic arthritis with a longer illness (IA), 
those with a shorter disease period (IB), and of healthy controls (IC)
Tabela I. Wyniki analizy statystycznej prób badanych populacji dzieci chorych na młodzieńcze idiopatyczne zapalenie stawów 
z długim (IA) i krótkim (IB) czasem trwania choroby oraz u dzieci grupy kontrolnej (IC)
Statistical Feature n Mean Me Min Max IQR SD SEM As SEAs
LEP-IA [ng/cm3] 22   5.85 1.24 37.5 7.74     2.24 0.64
LEP-IB [ng/cm3] 20   2.46 0.93 40.1 2.47     1.83 0.69
LEP (IA+IB) BMI < 23 [kg/m2] 28 2.01   0.93 3.63   0.98 0.35 0.48 0.75
LEP-IC [ng/cm3] 28   2.85 2.4 3.74 0.65     0.84 0.75
WBC-IA [G/L] 22   7.7 41 13.6 2.65     0.5 0.64
WBC-IB [G/L] 20   8.75 4.90 14.8 4.5     0.75 0.69
WBC-IC [G/L] 28   7.4 5.4 7.5 1.95     –0.64 0.75
LYMPH-IA (%) 22 39.13   16.8 61.6   12.57 3.63 0.21 0.64
LYMPH-IB (%) 20 35.39   12.7 63.9   14.87 4.7 0.42 0.69
LYMPH-IC (%) 28   7.4 5.4 7.5 1.95     –0.64 0.75
HBG-IA [g/dL] 22 12.13   9.4 15.1   1.41 0.41 0.26 0.64
HBG-IB [g/dL] 20 12.42   10.4 14.2   1.13 0.36 –0.29 0.69
HBG-IC [g/dL] 28   12.9 12.4 13.9 0.45     1.3 0.75
HCT-IA (%) 22 38.87   30.8 47.4   4.04 1.17 0.2 0.64
HCT-IB (%) 20 39.57   33.4 45.9   3.52 1.11 0.03 0.69
HCT-IC (%) 28   39 37 43 2     0.64 0.75
ESR-IA [mm/h] 22   12.5 4 40 12     1.12 0.64
ESR-IB [mm/h] 20 13   4 25   7.9 2.5 0.3 0.69
ESR-IC [mm/h] 28   2.5 1 5 2.35     0.53 0.75
BMI-IA  [kg/m2] 22 16.61   13.32 21.28   2.45 0.71 0.48 0.64
LEP/BMI-IA 22   0.33 0.09 1.76 0.59     1.49 0.64
BMI-IB [kg/m2] 20   15.89 13.82 29.94 4.95     1.48 0.69
LEP/BMI-IB 20   0.15 0.06 1.54 0.19     1.90 0.69
BMI-IC [kg/m2] 28 1.,91   17.16 20.41   0.95 0.34 –0.42 0.75
LEP/BMI-IC 28 0.15   0.13 0.20   0.03 0.01 0.47 0.75
Age-IA (years) 22 13.08   7 18   3.26 0.94 –0.39 0.64
Age-IB (years) 20 9.7   4 17   4.22 1.33 0.38 0.69
Age-IC (years) 28 11.25   8 15   2.82 1 0.02 0.75
Time Dis.-IA (months) 22   82 51 148 62     0.50 0.64
Time Dis.-IB (months) 20   8 2 18 7     2.23 0.69
N — sample size; Mean — arithmetic mean; Me — median; IQR — interquartile range; SD — standard deviation; SEM — standard error of the arithmetic mean; 
As — coefficient of unbalance (skewness); SEAs — asymmetry coefficient standard error; Min — minimum value in the studied statistical sample; Max — maximum 
value in the studied statistical sample
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The presence of these antibodies indicates that 
JIA is an autoimmune illness. As the individual ANA 
subtypes and titre were not analysed, we cannot fully 
confirm their presence as a sign of any disease or its 
intensification.
In chronic inflammatory diseases like in rheuma-
toid arthritis, there is an increase in cytokine markers, 
including IL-1, IL-2, IL-6, IL-8, interferon γ, and TNF-α. 
These markers are responsible not only for inflamma-
tion during illness, but they can also may increase ob 
gene expression and, consequently, stimulate leptin 
synthesis. In patients with JIA, pro-inflammatory 
cytokines activity increases basal metabolic rates, which 
reduces body mass and causes gradual devastation [8,9]. 
Some research has demonstrated that starving patients 
suffering from JIA results in a decrease in disease activity, 
which is correlated with lower serum concentrations 
of leptin; only considerable reduction of LEP stops 
disease progression. There are no unquestionable 
results concerning LEP for patients with chronic con-
nective tissue illnesses [7, 26]; there has been, however, 
speculation that leptin is involved in connective tissue 
systemic diseases. 
The tests carried out in this work confirm that 
leptin modulates the inflammatory process in juvenile 
idiopathic arthritis by causing various inflammatory 
mechanisms; however, the literature shows that the 
role of leptin in JIA has not yet been completely clari-
fied and requires more precise research on the subject. 
The results of this study helped to formulate fol-
lowing conclusions:
Conclusions
1. Children with juvenile idiopathic arthritis with 
BMI < 23 kg/m2 had lower leptin concentrations in 
comparison with healthy subjects.
2. Ill children with a shorter-term disease had a higher 
diversification of leptin concentration per BMI unit 
than the healthy controls.
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